TESARO price target raised to $51 from $43 at RW Baird Baird raised its price target on TESARO following its announced move into the immune-oncology space. The firm likes the deal and believes its fits nicely along its other businesses. Shares remain Outperform rated.
News For TSRO From The Last 14 Days
Check below for free stories on TSRO the last two weeks.
TESARO submits rolapitant NDA to FDA TESARO announced that it has submitted the New Drug Application, or NDA, for oral rolapitant to the FDA. Rolapitant is an investigational neurokinin-1 receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting.